AI-generated from publicly available materials.Cellares has secured its second partnership with an Asia-based organization in just over a week, marking a significant step in its automated cell therapy manufacturing efforts. This latest collaboration is with Seoul National University Hospital (SNUH) in South Korea, where the focus will be on evaluating the integration of SNUH’s gene-modified hematopoietic stem and progenitor cell manufacturing process into Cellares' Cell Shuttle platform.
The partnership aims to test an investigational cell therapy targeting paroxysmal nocturnal hemoglobinuria (PNH) using a two-step transfection workflow. Cellares' Cell Shuttle features an integrated electroporator that automates several manufacturing steps, which CEO Fabian Gerlinghaus describes as a “lab in a box.” This technology is designed to enhance efficiency in cell therapy production, particularly for non-viral approaches, as highlighted in a recent agreement with Taiwan's GenomeFrontier Therapeutics.
Despite experiencing setbacks earlier this summer, including the loss of a significant customer, Cellares continues to expand its partner network. Gerlinghaus noted that while not every partnership will lead to successful outcomes, the company has signed a dozen customers this year and aims to build a substantial portfolio. He expressed confidence in the strategy moving forward, emphasizing that the focus remains on achieving commercial manufacturing milestones.
As Cellares navigates its growth trajectory, the company appears undeterred by past challenges. The emphasis on automation and innovative manufacturing processes positions Cellares as a key player in the evolving landscape of cell therapy, potentially paving the way for future clinical developments.